ArticleNature communications2025
Apolipoprotein-A1 transports and regulates MMP2 in the blood.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural basis for lipid binding by the blood protein vitronectin, a component of HDL.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Synthesized in the liver and intestines, apolipoprotein A1 (APOA1) transports cholesterol in high density lipoproteins from atherosclerotic lesions to the liver, protecting against atherosclerotic plaque rupture. Here, we show that proMMP2 (zymogen of matrix metalloproteinase-2) circulates associated with APOA1 in humans and APOA1-expressing mice. This is noteworthy because MMP2 is the most abundant MMP in blood, and MMPs promote atherosclerotic plaque rupture. Artificial intelligence (AlphaFold)-based modeling suggested that APOA1 and MMP2 interact; direct interactions were confirmed using five orthogonal interaction assays, showing that APOA1 binds to MMP2 catalytic and hemopexin-like domains. APOA1 inhibited MMP2 autolysis and allosterically increased MMP2 activity-an effect specifically reproduced by plasma from humans and APOA1-expressing mice but not albumin nor plasma from APOA1 knockout mice. These function-altering interactions with APOA1 may increase MMP2 bioavailability and lay the foundation for future research on how apolipoproteins and MMPs influence atherosclerotic plaque rupture, independently of cholesterol transport.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.